These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 36689809)

  • 21. Discovery and mechanism of action of Thonzonium bromide from an FDA-approved drug library with potent and broad-spectrum inhibitory activity against main proteases of human coronaviruses.
    Wang R; Zhai G; Zhu G; Wang M; Gong X; Zhang W; Ge G; Chen H; Chen L
    Bioorg Chem; 2023 Jan; 130():106264. PubMed ID: 36395603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
    Hirose Y; Shindo N; Mori M; Onitsuka S; Isogai H; Hamada R; Hiramoto T; Ochi J; Takahashi D; Ueda T; Caaveiro JMM; Yoshida Y; Ohdo S; Matsunaga N; Toba S; Sasaki M; Orba Y; Sawa H; Sato A; Kawanishi E; Ojida A
    J Med Chem; 2022 Oct; 65(20):13852-13865. PubMed ID: 36229406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methyl rosmarinate is an allosteric inhibitor of SARS-CoV-2 3 CL protease as a potential candidate against SARS-cov-2 infection.
    Li H; Sun M; Lei F; Liu J; Chen X; Li Y; Wang Y; Lu J; Yu D; Gao Y; Xu J; Chen H; Li M; Yi Z; He X; Chen L
    Antiviral Res; 2024 Apr; 224():105841. PubMed ID: 38408645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.
    Sasaki M; Tabata K; Kishimoto M; Itakura Y; Kobayashi H; Ariizumi T; Uemura K; Toba S; Kusakabe S; Maruyama Y; Iida S; Nakajima N; Suzuki T; Yoshida S; Nobori H; Sanaki T; Kato T; Shishido T; Hall WW; Orba Y; Sato A; Sawa H
    Sci Transl Med; 2023 Jan; 15(679):eabq4064. PubMed ID: 36327352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Production of a functionally active recombinant SARS-CoV-2 (COVID-19) 3C-like protease and a soluble inactive 3C-like protease-RBD chimeric in a prokaryotic expression system.
    De Marco Verissimo C; López Corrales J; Dorey AL; Cwiklinski K; Lalor R; Calvani NED; Jewhurst HL; Flaus A; Doyle S; Dalton JP
    Epidemiol Infect; 2022 Jun; 150():e128. PubMed ID: 35723031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
    Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
    Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease.
    Amblard F; LeCher JC; De R; Zhou S; Liu P; Goh SL; Tao S; Patel D; Downs-Bowen J; Zandi K; Zhang H; Chaudhry G; McBrayer T; Muczynski M; Al-Homoudi A; Engel J; Lan S; Sarafianos SG; Kovari LC; Schinazi RF
    Eur J Med Chem; 2024 Mar; 268():116263. PubMed ID: 38432056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation.
    Bei ZC; Yu H; Wang H; Li Q; Wang B; Zhang D; Xu L; Zhao L; Dong S; Song Y
    Emerg Microbes Infect; 2023 Dec; 12(1):2211688. PubMed ID: 37144395
    [No Abstract]   [Full Text] [Related]  

  • 30. Elucidation of the inhibitory activity of plant-derived SARS-CoV inhibitors and their potential as SARS-CoV-2 inhibitors.
    Bello M; Hasan MK
    J Biomol Struct Dyn; 2022; 40(20):9992-10004. PubMed ID: 34121618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction of Laurusides 1 and 2 with the 3C-like Protease (M
    Autiero I; Roviello GN
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982585
    [No Abstract]   [Full Text] [Related]  

  • 32. Discovery of natural catechol derivatives as covalent SARS-CoV-2 3CL
    Wang F; Liu D; Gao D; Yuan J; Zhao J; Yuan S; Cen Y; Lin GQ; Zhao J; Tian P
    Int J Biol Macromol; 2024 Apr; 264(Pt 1):130377. PubMed ID: 38395279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
    Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0063222. PubMed ID: 36094202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring 2-methyl-substituted vitamin K
    Koharazawa R; Hayakawa M; Takeda K; Miyazaki K; Tode C; Hirota Y; Suhara Y
    Bioorg Med Chem Lett; 2024 Mar; 100():129642. PubMed ID: 38310976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bioactive compounds of Jingfang Granules against SARS-CoV-2 virus proteases 3CL
    Shang ZP; Yi Y; Yu R; Fan JJ; Huang YX; Qiao X; Ye M
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):907-919. PubMed ID: 36241233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors.
    Moghadasi SA; Heilmann E; Khalil AM; Nnabuife C; Kearns FL; Ye C; Moraes SN; Costacurta F; Esler MA; Aihara H; von Laer D; Martinez-Sobrido L; Palzkill T; Amaro RE; Harris RS
    Sci Adv; 2023 Mar; 9(13):eade8778. PubMed ID: 36989354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir.
    Kiso M; Yamayoshi S; Iida S; Furusawa Y; Hirata Y; Uraki R; Imai M; Suzuki T; Kawaoka Y
    Nat Commun; 2023 Jul; 14(1):4231. PubMed ID: 37454219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.
    He J; Hu L; Huang X; Wang C; Zhang Z; Wang Y; Zhang D; Ye W
    Int J Antimicrob Agents; 2020 Aug; 56(2):106055. PubMed ID: 32534187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Danshensu inhibits SARS-CoV-2 by targeting its main protease as a specific covalent inhibitor and discovery of bifunctional compounds eliciting antiviral and anti-inflammatory activity.
    Wang R; Chen X; Li H; Chen X; Sun D; Yu D; Lu J; Xie Y; Zhang Q; Xu J; Zhang W; Chen H; Liu S; Chen L
    Int J Biol Macromol; 2024 Feb; 257(Pt 2):128623. PubMed ID: 38070810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.